Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Intriguing Research Brings Hope to Orthopedic Oncology

October 22nd 2019

R. Lor Randall, MD, FACS, discusses ongoing studies and treatment options in the orthopedic oncology landscape.

Neoadjuvant Immunotherapy Plus Radiation Shows Promise in Soft Tissue Sarcoma

October 22nd 2019

Vincent Y. Ng, MD, discusses what implications the NEXIS study could have in soft tissue sarcoma treatment and the next steps going forward.

Dr. Gibbs on Predicting Response to Treatment in Osteosarcoma

October 21st 2019

C. Parker Gibbs Jr., MD, discusses the use of cell cycle checkpoint regulators to indicate response to treatment in osteosarcoma.

Dr. Nasri on Risk Stratification in Osteosarcoma

October 16th 2019

Elham Nasri, MD, fellow, Bone and Soft Tissue Pathology, University of Florida, discusses risk stratification in osteosarcoma.

Open-Minded Research for Therapeutic Options Needed in TGCT

October 10th 2019

William Eward, MD, DVM, discusses the use of pexidartinib and other options to treat patients with tenosynovial giant cell tumor, as well as future recommendations for the field, such as using comparative oncology when researching drugs.

Dr. Randall on Using Pexidartinib to Treat Tenosynovial Giant Cell Tumor

October 9th 2019

R. Lor Randall, MD, FACS, discusses using pexidartinib to treat tenosynovial giant cell tumor.

NCCN Grants Category 1 Recommendation to Pexidartinib for TGCT

September 27th 2019

The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma to include a category 1 recommendation for pexidartinib (Turalio) for the treatment of patients with tenosynovial giant cell tumor.

FDA Grants Nirogacestat Breakthrough Designation for Desmoid Tumors

September 4th 2019

The FDA has granted a breakthrough therapy designation to the investigational gamma-secretase inhibitor nirogacestat (PF-03084014) for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis.

Dr. D'Angelo on Bempegaldesleukin/Nivolumab Combo in Sarcomas

September 3rd 2019

Sandra P. D’Angelo, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the results of a pilot study investigating the combination of bempegaldesleukin (NKTR-214) plus nivolumab (Opdivo) in patients with sarcomas.

Dr. Hurwitz on Patient Cohorts in the PIVOT-02 Trial

August 30th 2019

Michael E. Hurwitz, MD, PhD, assistant professor of medicine, Yale Cancer, Center, discusses the various patient cohorts in the ongoing phase I/II PIVOT-02 trial.

FDA Approves Pexidartinib for Tenosynovial Giant Cell Tumor

August 2nd 2019

The FDA has approved pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor that is associated with severe morbidity or functional limitations and not responsive to improvement with surgery.

FDA Grants Priority Review to Tazemetostat for Epithelioid Sarcoma

July 25th 2019

The FDA has granted a priority review to tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.

Fresh Approaches to RT Improve Outcomes in Retroperitoneal Sarcoma

July 15th 2019

Each year, 10% to 15% of patients with soft-tissue carcinomas receive a diagnosis of rare retroperitoneal sarcoma (RPS), an aggressive disease that typically recurs in 26% of cases and has a 47% to 67% five-year overall survival rate. New radiation therapies hold potential to decrease treatment time and provide local control of RPS.

Investigators Express Confidence in a Novel TKI That Targets Rare Sarcomas

June 26th 2019

Anlotinib, a novel tyrosine kinase inhibitor capable of mounting a multipronged attack against oncogenic processes, is being tested in rare soft tissue sarcoma subtypes where patients have limited therapeutic options.

FDA Approval Sought for Tazemetostat for Epithelioid Sarcoma

May 30th 2019

A new drug application has been submitted to the FDA for tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.

Dr. Navai on Treatment Options in Relapsed/Refractory Sarcoma

May 17th 2019

Shoba A. Navai, MD, an assistant professor, Department of Pediatrics, Section of Pediatric Hematology and Oncology, at Baylor College of Medicine, Texas Children’s Hospital, discusses treatment options for patients with relapsed/refractory sarcoma.

FDA Panel Backs Pexidartinib for Tenosynovial Giant Cell Tumor

May 14th 2019

The FDA’s Oncologic Drugs Advisory Committee voted in favor of pexidartinib for an indication as a treatment of adult patients with symptomatic tenosynovial giant cell tumor.

FDA Grants Pomalidomide Breakthrough Designation in Kaposi Sarcoma

May 13th 2019

The FDA has granted a breakthrough therapy designation to pomalidomide for use as a treatment for patients with HIV-positive Kaposi sarcoma who have received prior chemotherapy, as well as patients with HIV-negative Kaposi sarcoma.

Dr. Schlumbrecht on Investigational Treatment Strategies in Uterine Leiomyosarcoma

May 9th 2019

Matthew P. Schlumbrecht, MD, associate professor and co-director of Cancer Prevention and Control, Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses investigational treatment strategies in uterine leiomyosarcoma.

EU Panel Recommends Revoking Olaratumab in Soft Tissue Sarcoma

April 29th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended that the conditional marketing authorization for olaratumab be revoked following results of the ANNOUNCE study, which did not demonstrate a survival benefit with the PDGFRα antagonist in combination with doxorubicin versus doxorubicin alone in patients with advanced or metastatic soft tissue sarcoma.